Opsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody.
about
Cryptococcus neoformans: historical curiosity to modern pathogenCryptococcal interactions with the host immune system.Opsonic requirements for dendritic cell-mediated responses to Cryptococcus neoformans.Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans.A sensitive high-throughput assay for evaluating host-pathogen interactions in Cryptococcus neoformans infectionContribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.Quantitative analysis of phagocytosis and killing of Cryptococcus neoformans by human peripheral blood mononuclear cells by flow cytometry.Antibody immunity and invasive fungal infectionsAcute lethal toxicity following passive immunization for treatment of murine cryptococcosisMonoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice.Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformansAntibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infectionDissociation of a hydrophobic surface from phagocytosis of encapsulated and non-encapsulated cryptococcus neoformans.Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization.Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cellProtective murine monoclonal antibodies to Cryptococcus neoformansGrowth inhibition of Cryptococcus neoformans by cultured human monocytes: role of the capsule, opsonins, the culture surface, and cytokines.Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide.Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity.Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responsesProtection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody.Localization on encapsulated Cryptococcus neoformans of serum components opsonic for phagocytosis by macrophages and neutrophilsAntibody-dependent natural killer cell-mediated growth inhibition of Cryptococcus neoformans.Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan.Prevalence in Cryptococcus neoformans strains of a polysaccharide epitope which can elicit protective antibodies.Adaptive Immunity to Cryptococcus neoformans Infections.
P2860
Q27025924-3A81A151-D163-4BF8-82FC-5EF6D6947DC5Q30387948-13E549CF-475E-4F46-B8E2-F4D49ABC2C44Q33559279-0B46D570-485F-4C51-9664-AB4C60E432D3Q33751411-0F993035-0623-45ED-8244-176502224208Q33754371-F838F33C-1423-4F9D-9F86-A17C7400B920Q33987858-917278AF-1587-4A03-8C6C-8A7374E58210Q34779166-7A3D69AF-2776-431D-A9BC-2995753B711BQ35225136-331FE053-DA79-4020-B956-4BB8155AAC81Q35447692-ADD2AD63-FBDF-4803-A385-DB3F9CC55F17Q35546751-BCAC1969-3F98-41FD-86FC-0D5ECDD07191Q35775466-B1B783D1-AB4C-49FB-B8C0-8066D19F649CQ35923662-1FA8A73A-7302-41F9-B82C-832F3832118CQ36255421-15D9AF4E-A6A0-4894-997B-60432DD53713Q36346286-F869441E-0C2A-4474-A108-AB6ABC134BC0Q36361541-2FC51D35-D1EC-421C-9B2E-7C9727DD56B6Q36364342-C19CE5E7-3097-4699-AF29-D5F4E7C3B1D3Q36969771-C6E95F6C-1341-49DD-8C7B-DB08598B6349Q36980669-7F203177-978E-4FE5-8794-536FD7FF811FQ36984485-A99F0559-E842-44E1-8335-0E6CB73FED86Q36988205-04C3D5C6-5F20-4CC7-8D5B-0F34A083A469Q36988622-888CBA80-D058-4930-8906-CBC476CA9D80Q37017360-292D6179-0F43-4EF8-8956-60F3645A5AC4Q37098843-F1E6649F-7512-4F83-BF13-94F9F94B62A2Q40172343-E097E77A-5CB7-4EEE-9AF3-AAB1982BE3ACQ40374574-B2A57593-B562-45C9-AC5C-9573EEDE8D79Q40673168-A05A31C1-553B-4520-92B5-C1517C8ED920Q49188733-D4AE0CB6-D626-4122-AD6A-5B1F15EC6C47
P2860
Opsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody.
description
1981 nî lūn-bûn
@nan
1981年の論文
@ja
1981年学术文章
@wuu
1981年学术文章
@zh-cn
1981年学术文章
@zh-hans
1981年学术文章
@zh-my
1981年学术文章
@zh-sg
1981年學術文章
@yue
1981年學術文章
@zh
1981年學術文章
@zh-hant
name
Opsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody.
@ast
Opsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody.
@en
type
label
Opsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody.
@ast
Opsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody.
@en
prefLabel
Opsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody.
@ast
Opsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody.
@en
P2860
P1476
Opsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody
@en
P2093
J L Follette
P2860
P304
P407
P577
1981-03-01T00:00:00Z